MedTrace Logo

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

NCT00093028 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2010-07-02

No results posted yet for this study

Summary

The purpose of this study is

* to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™),
* to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment,
* to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).

Conditions

Interventions

DRUG

CC-5013 (Revlimid™)

N/A Study Complete

DRUG

bortezomib

N/A Study Complete

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Bart Barlogie, M.D., Ph.D. · UAMS Myeloma Institute for Research & Therapy

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00093028 on ClinicalTrials.gov